Alteplase drug data and news

Alteplase drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.

Generic name

Alteplase

Brand Names/Synonyms

Tissue-type plasminogen activator precursor;tPA;t- PA;t-plasminogen activator;Alteplase;Reteplase; Activase (Genentech Inc)

Indication

For management of acute myocardial infarction, acute ischemic strok and for lysis of acute pulmonary emboli

Sponsored links

Description

Human tissue plasminogen activator, purified, glycosylated, 527 residues purified from CHO cells

Pharmacology

Activase binds to fibrin in a thrombus and converts the entrapped plasminogen to plasmin. It also produces limited conversion of plasminogen in the absence of fibrin.

Mechanism Of Action

Cleaves the Arg-Val bond in plasminogen to produce active plasmin.

Alteplase News
(When available)

Nuvelo and Bayer HealthCare Begin SONOMA-3, Second Phase 3 Trial ... Feb 27, 2006
...dose, respectively. By comparison, Cathflo(R)Activase(R) (alteplase) did not restore flow at either time point. Alfimeprase also ... - International News Service,

Nuvelo and Bayer begin second alfimeprase trial Feb 28, 2006
...minutes after the first dose, respectively. By comparison, CathfloActivase (alteplase) did not restore flow at either time point. - Pharmaceutical Business Review

Nuvelo and Bayer HealthCare Begin SONOMA-3, Second Phase 3 Trial ... Feb 27, 2006
...first dose, respectively. By comparison, Cathflo®Activase® (alteplase) did not restore flow at either time point. Alfimeprase also ... - Yahoo! News (press release)

ASA: ReoPro-Retavase Duo Promising as Late Reperfusion Stroke ... Feb 20, 2006
...planned as a 72-patient trial of targeted thrombolytic therapies initiated after the three-hour window approved for treatment with Activase (alteplase [rt-PA ... - MedPage Today,

New England Journal of Medicine Publishes NXY-059 Study, The First ... Feb 8, 2006
The incidence of symptomatic intracranial hemorrhage (ICH) in patients treated with NXY-059 and alteplase, a tissue plasminogen activator (rt-PA), was lower ... - Antara,

Analysis: AstraZ's stroke drug promising Feb 8, 2006
The research team noted that among patients who also received alteplase, those receiving NXY-059 had a lower incidence of any hemorrhagic transformation and ... - United Press International

FibroGen Reports FG-4539, HIF-PH Inhibitor, is Neuroprotective and ... Feb 17, 2006
The US Food and Drug Administration has approved tissue plasminogen activator, or tPA, (ie, Alteplase) to treat ischemic stroke. ... - Genetic Engineering News,

Thrombolytic Treatment Before Stenting Linked to Increased ... Feb 14, 2006
There was increased mortality only in patients who were pre-treated with thrombolytics such as TNKase (tenecteplase) or Activase (alteplase). ... - MedPage Today,

Neuroprotective Agent Improves Outcome After Ischemic Stroke Feb 9, 2006
...with placebo. The subset of patients who also received alteplase had a lower incidence of intracranial hemorrhage. "Neuroprotective ... - Medscape (subscription)

NXY-059 for Acute Ischemic Stroke Feb 9, 2006
In a post hoc analysis of patients who also received alteplase, NXY-059 was associated with a lower incidence of any hemorrhagic transformation (P=0.001) and ... - New England Journal of Medicine (subscription),

NXY-059 for acute ischemic stroke Feb 9, 2006
The incidence of symptomatic intracranial hemorrhage in patients treated with NXY-059 and Alteplase, a tissue plasminogen activator ( rt-PA ), was lower than ... - Xagena.it,

Dosage Forms

POWDER FOR SOLUTION

Drug_Category

Thrombolytic Agents

Absorption

Not Available

Interactions

Not Available

Toxicity

Not Available

Organisms Affected

Humans and other mammals

Chemical IUPAC Name

Human tissue plasminogen activator

Chemical Formula

C2569H3928N746O781S40

Molecular Weight

59042.3

Smiles String

Not Available

Melting Point

60 oC (Novokhatny, V.V. et al., J. Biol. Chem. 266:12994-123002 (1991))

Water Solubility

Not Available

State

Transparent, slightly viscous, aqueous liquid

LogP/Hphobicity

-0.516

Isoelectric Point

7.61

Biotransformation

Not Available

Half Life

Not Available

Protein Binding [%]

Not Available

RxList Link

RXlist

Sponsored links

Drug Reference

http://www.rxlist.com/cgi/generic/alteplas.htm

Drug Type

Approved Drug

Accession No

BIOD00050

CAS Registry Number

105857-23-6

KEGG Compound ID

Not Available

PubChem ID

Not Available

PharmGKB ID

PA10012

SwissProt ID

TPA_HUMAN (P00750)

GenBank ID

L00153

Drug ID Number [DIN]

2245859